AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Oramed Pharmaceuticals Inc. Remuneration Information 2021

Jul 29, 2021

6965_rns_2021-07-29_cb690d72-f02a-4c94-b6fc-cf90bbf6670c.htm

Remuneration Information

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

_________ false


��	2 381
ORAMED PHARMACEUTICALS INC
Corporation no: 980376008	13866
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C003 ( Public )		Reported via MAGNA:	29/07/2021
	www.isa.gov.il			www.tase.co.il				Reference:	2021-02-059239	Time of broadcast: 00:17 00:17

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.


Attached hereto is a report on	Form DEF 14A - Definitive Proxy Statement

ORAMEDPHARMINC_DEF14A_20210728_isa.pdf



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 15/06/2021
Address: Avenue of the Americas 01185 , New York 10036 New York , USA Tel: 844-9672633 , 02-5660001 Fax: 02-5660004
E-mail address: [email protected] Company site: www.oramed.com

Previous names of reporting entity:

Name of the Signatory: SILBERMAN DAVID JOSEPH BENJAMIN Position of Signatory in the reporting corporation: Chief Financial Officer Name of Employer Company:
Address: Mamila 20 , Jerusalem 9414409 Telephone: 02-5788763 Facsimile: - E-mail: [email protected] 2
USA